These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 11956118

  • 1. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events.
    Ridker PM, Shih J, Cook TJ, Clearfield M, Downs JR, Pradhan AD, Weis SE, Gotto AM, Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Investigators.
    Circulation; 2002 Apr 16; 105(15):1776-9. PubMed ID: 11956118
    [Abstract] [Full Text] [Related]

  • 2. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines.
    Clearfield M, Downs JR, Lee M, Langendorfer A, McConathy W, Gotto AM.
    Am J Cardiol; 2005 Dec 15; 96(12):1674-80. PubMed ID: 16360356
    [Abstract] [Full Text] [Related]

  • 3. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendörfer A, Beere PA, Watson DJ, Downs JR, de Cani JS.
    Eur Heart J; 2000 Oct 15; 21(19):1627-33. PubMed ID: 10988016
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec 15; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 5. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
    Cui Y, Watson DJ, Girman CJ, Shapiro DR, Gotto AM, Hiserote P, Clearfield MB.
    Am J Cardiol; 2009 Sep 15; 104(6):829-34. PubMed ID: 19733719
    [Abstract] [Full Text] [Related]

  • 6. Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Gotto AM.
    Atheroscler Suppl; 2007 Aug 15; 8(2):3-8. PubMed ID: 17588826
    [Abstract] [Full Text] [Related]

  • 7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM.
    JAMA; 1998 May 27; 279(20):1615-22. PubMed ID: 9613910
    [Abstract] [Full Text] [Related]

  • 8. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women.
    Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, Stein EA, Langendorfer A, Beere PA, Gotto AM.
    J Womens Health Gend Based Med; 2001 Dec 27; 10(10):971-81. PubMed ID: 11788107
    [Abstract] [Full Text] [Related]

  • 9. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S, Ridker PM.
    Am J Cardiol; 2006 Jan 16; 97(2A):33A-41A. PubMed ID: 16442935
    [Abstract] [Full Text] [Related]

  • 10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 16; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 11. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
    Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM, Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators.
    N Engl J Med; 2001 Jun 28; 344(26):1959-65. PubMed ID: 11430324
    [Abstract] [Full Text] [Related]

  • 12. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB, Weis SE, Willis JM, Vasenius KA, McConathy WJ.
    J Am Osteopath Assoc; 2002 Jul 28; 102(7):377-84. PubMed ID: 12138952
    [Abstract] [Full Text] [Related]

  • 13. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
    Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Trial Study Group.
    Am J Cardiol; 2007 Dec 01; 100(11):1659-64. PubMed ID: 18036365
    [Abstract] [Full Text] [Related]

  • 14. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S, MIRACL Study Investigators.
    J Am Coll Cardiol; 2009 Jun 09; 53(23):2186-96. PubMed ID: 19497447
    [Abstract] [Full Text] [Related]

  • 15. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin.
    Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, Zagrebelsky V, Weis S, Shapiro DR, Beere PA, Gotto AM.
    Am J Cardiol; 2001 May 01; 87(9):1074-9. PubMed ID: 11348605
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E.
    J Am Coll Cardiol; 2008 Sep 09; 52(11):914-20. PubMed ID: 18772061
    [Abstract] [Full Text] [Related]

  • 18. Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction.
    Matetzky S, Freimark D, Ben-Ami S, Goldenberg I, Leor J, Doolman R, Novikov I, Eldar M, Hod H.
    Arch Intern Med; 2003 Sep 08; 163(16):1933-7. PubMed ID: 12963566
    [Abstract] [Full Text] [Related]

  • 19. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.
    Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E.
    Circulation; 2006 Jul 25; 114(4):281-8. PubMed ID: 16847150
    [Abstract] [Full Text] [Related]

  • 20. Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c.
    Hajer GR, van der Graaf Y, Bots ML, Algra A, Visseren FL, SMART Study Group.
    Eur J Clin Invest; 2009 Aug 25; 39(8):680-8. PubMed ID: 19453647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.